Table 2.
Clinical characteristics of the sample. Data are presented as the mean (SD) and/or number (%).
| Variable | Obs/Freq | Mean/Percentage∗ | Std. Err. | [95% Conf. Interval] | ||
|---|---|---|---|---|---|---|
| MINI | GAD | 77 | 87.5% | 0.03 | 0.78 | 0.92 |
| MDD | 67 | 76.13% | 0.04 | 0.65 | 0.83 | |
| Panic disorder | 56 | 63.6% | 0.05 | 0.52 | 0.73 | |
| Social phobia/Agoraphobia | 26 | 29.5% | 0.04 | 0.20 | 0.40 | |
| Dysthymia | 10 | 11.3% | 0.03 | 0.06 | 0.19 | |
| OCD | 3 | 3.4% | 0.01 | 0.01 | 0.10 | |
|
| ||||||
| HADS | HADS-D | 88 | 12.04 | 0.46 | 11.12 | 12.96 |
| HADS-A | 88 | 14.34 | 0.39 | 13.55 | 15.12 | |
| AIS | 88 | 14.13 | 0.52 | 13.10 | 15.17 | |
| SWLS | 87 | 11.78 | 0.49 | 10.79 | 12.76 | |
| VAS pain | 88 | 6.57 | 0.23 | 6.11 | 7.03 | |
| PDI | 88 | 46.12 | 1.21 | 43.71 | 48.53 | |
| Onset of pain | 86 | 35.44 | 1.29 | 32.87 | 38.02 | |
| Diagnosis of fibromyalgia | 87 | 44.55 | 0.92 | 42.73 | 46.37 | |
| S-FIQ | 87 | 55.58 | 1.06 | 53.47 | 57.69 | |
| Suicidal thinking | 73 | 82.9% | 0.04 | 0.73 | 0.89 | |
|
| ||||||
| Suicide attempt | 28 | 32.9% | 0.05 | 0.23 | 0.43 | |
| Violent | 4 | 4.5% | 0.02 | 0.01 | 0.11 | |
| No violent | 24 | 27.2% | 0.04 | 0.18 | 0.37 | |
| Severe | 12 | 13.6% | 0.03 | 0.078 | 0.22 | |
| Not severe | 16 | 18.1% | 0.04 | 0.11 | 0.27 | |
|
| ||||||
| Diagnostics axis III | CFS | 53 | 60.2% | 0.05 | 0.49 | 0.70 |
| Osteoarthritis | 27 | 30.6% | 0.04 | 0.21 | 0.41 | |
| Spinal disc herniation | 10 | 11.3% | 0.03 | 0.06 | 0.19 | |
| Chronic migraine | 9 | 10.2% | 0.03 | 0.05 | 0.18 | |
| Low back pain | 9 | 10.2% | 0.03 | 0.05 | 0.18 | |
| Thyroid diseases | 8 | 9% | 0.03 | 0.04 | 0.17 | |
| Rheumatoid arthritis | 6 | 6.8% | 0.02 | 0.03 | 0.14 | |
| Restless legs syndrome | 5 | 5.6% | 0.02 | 0.02 | 0.13 | |
| Chemical sensitivity syndrome | 4 | 4.5% | 0.02 | 0.01 | 0.11 | |
|
| ||||||
| Pharmacological treatment | Anxiolytics/Hypnotics | 53 | 60.9% | 0.05 | 0.50 | 0.70 |
| SNRI | 43 | 49.4% | 0.05 | 0.38 | 0.59 | |
| SSRI | 18 | 20.6% | 0.04 | 0.13 | 0.30 | |
| Other antidepressants | 33 | 37.9% | 0.05 | 0.28 | 0.48 | |
| Opioids+ Tramadol Codeine Morphine Fentanyl Oxycodone Buprenorphine Tapentadol | 32 20 1 1 1 2 1 8 |
36.7% 22.7% 1.1% 1.1% 1.1% 2.3% 1.1% 9.1% |
0.05 0.04 0.01 0.01 0.01 0.01 0.01 0.03 |
0.27 0.14 −0.01 −0.01 −0.01 −0.01 −0.01 0.03 |
0.47 0.32 0.03 0.03 0.03 0.06 0.03 0.16 |
|
| Paracetamol | 32 | 36.7% | 0.05 | 0.27 | 0.47 | |
| Anti-inflammatory drugs | 31 | 35.6% | 0.05 | 0.26 | 0.46 | |
| Anticonvulsants | 18 | 20.6% | 0.04 | 0.13 | 0.30 | |
| Antipsychotics | 8 | 9.1% | 0.03 | 0.04 | 0.17 | |
Obs/Freq : Number of cases observed/Frequency; Std. Error, Standard Error; Conf., Confidence; MINI : MINI Neuropsychiatric International Interview; MDD : Major Depressive Disorder; GAD : Generalized Anxiety Disorder; OCD : Obsessive-Compulsive Disorder; HADS : Hospital Anxiety and Depression Scale; HADS-D : Hospital Anxiety and Depression Scale-Depression; HADS-A : Hospital Anxiety and Depression Scale-Anxiety; AIS : Athens Insomnia Scale; SWLQ : Satisfaction With Life Questionnaire; VAS pain, Visual Analogue Scale for pain; PDI : Pain Disability Index; S-FIQ : Fibromyalgia Impact Questionnaire-Spanish validation; CFS : Chronic Fatigue Syndrome; SSRI : Selective Serotonin Reuptake Inhibitor; SNRI : Serotonin-Norepinephrine Reuptake Inhibitor. ∗Scales data are presented as means. The rest of the variables are presented as percentages. + also in combination.